These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14559835)

  • 1. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
    van Herwaarden AE; Jonker JW; Wagenaar E; Brinkhuis RF; Schellens JH; Beijnen JH; Schinkel AH
    Cancer Res; 2003 Oct; 63(19):6447-52. PubMed ID: 14559835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
    Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.
    van Herwaarden AE; Wagenaar E; Karnekamp B; Merino G; Jonker JW; Schinkel AH
    Carcinogenesis; 2006 Jan; 27(1):123-30. PubMed ID: 16000399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
    Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
    Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.
    Pavek P; Merino G; Wagenaar E; Bolscher E; Novotna M; Jonker JW; Schinkel AH
    J Pharmacol Exp Ther; 2005 Jan; 312(1):144-52. PubMed ID: 15365089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
    Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.
    Merino G; Jonker JW; Wagenaar E; van Herwaarden AE; Schinkel AH
    Mol Pharmacol; 2005 May; 67(5):1758-64. PubMed ID: 15709111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The colon carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is actively secreted in the distal colon of the rat: an integrated view on the role of PhIP transport and metabolism in PhIP-induced colon carcinogenesis.
    Nicken P; Schröder B; von Keutz A; Breves G; Steinberg P
    Arch Toxicol; 2013 May; 87(5):895-904. PubMed ID: 23306951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
    Merino G; Alvarez AI; Pulido MM; Molina AJ; Schinkel AH; Prieto JG
    Drug Metab Dispos; 2006 Apr; 34(4):690-5. PubMed ID: 16434544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.
    Durmus S; van der Valk M; Teunissen SF; Song JY; Wagenaar E; Beijnen JH; Schinkel AH
    Arch Toxicol; 2019 Mar; 93(3):775-790. PubMed ID: 30701287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeic acid inhibits the uptake of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by inducing the efflux transporters expression in Caco-2 cells.
    Hong YJ; Yang SY; Nam MH; Koo YC; Lee KW
    Biol Pharm Bull; 2015; 38(2):201-7. PubMed ID: 25399682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
    Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
    Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
    Schutte ME; Freidig AP; van de Sandt JJ; Alink GM; Rietjens IM; Groten JP
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):204-15. PubMed ID: 16997339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.
    Dietrich CG; Vehr AK; Martin IV; Gassler N; Rath T; Roeb E; Schmitt J; Trautwein C; Geier A
    Int J Cancer; 2011 Aug; 129(3):546-52. PubMed ID: 21544799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta.
    Myllynen P; Kummu M; Kangas T; Ilves M; Immonen E; Rysä J; Pirilä R; Lastumäki A; Vähäkangas KH
    Toxicol Appl Pharmacol; 2008 Oct; 232(2):210-7. PubMed ID: 18680760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
    Enokizono J; Kusuhara H; Ose A; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2008 Jun; 36(6):995-1002. PubMed ID: 18322075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.